Bharatbook.com added a new report on "Stakeholder Opinions Hematopoietic Stem Cell Transplantation In need of further research and development" into its market report catalogue for reselling.
Online PR News – 02-January-2010 – – Stakeholder Opinions Hematopoietic Stem Cell Transplantation In need of further research and development
Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes. ( http://www.bharatbook.com/detail.asp?id=98228&rt=Stakeholder-Opinions-Hematopoietic-Stem-Cell-Transplantation-In-need-of-further-research-and-development.html )
* Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens
* Discussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trends
* Unmet needs and research priorities in the field of HSCT
* Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
The use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely.
The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy.
The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential.
Reasons to Purchase
* Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimens
* Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease
* Identify unmet needs and research priorities in the field of HSCT
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=98228&rt=Stakeholder-Opinions-Hematopoietic-Stem-Cell-Transplantation-In-need-of-further-research-and-development.html
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: http://twitter.com/3bbharatbook